Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment

被引：42

作者：

Ellaithy, Amr ^{[1
]}

Younkin, Jason ^{[1
]}

Gonzalez-Maeso, Javier ^{[1
,2
,3
,4
]}

Logothetis, Diomedes E. ^{[1
]}

机构：

[1] Virginia Commonwealth Univ, Sch Med, Dept Physiol & Biophys, Richmond, VA 23298 USA

[2] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA

[3] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA

来源：

TRENDS IN NEUROSCIENCES | 2015年 / 38卷 / 08期

基金：

美国国家卫生研究院;

关键词：

schizophrenia; mGlu(2)R; 5-HT2A; PAMs; HDAC2; epigenetics; PREFRONTAL CORTEX; HALLUCINOGENIC DRUG; SIGNALING PATHWAYS; OPIOID RECEPTOR; MOTOR BEHAVIORS; GENE-EXPRESSION; MGLUR2; RECEPTOR; FUNCTIONAL-ROLE; MESSENGER-RNA; POTENTIATORS;

D O I：

10.1016/j.tins.2015.06.002

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The past two decades have witnessed a rise in the 'NMDA receptor hypofunction' hypothesis for schizophrenia, a devastating disorder that affects around 1% of the population worldwide. A variety of presynaptic, postsynaptic, and regulatory proteins involved in glutamatergic signaling have thus been proposed as potential therapeutic targets. This review focuses on positive allosteric modulation of metabotropic glutamate 2 receptors (mGlu(2)Rs) and discusses how recent preclinical epigenetic data may provide a molecular explanation for the discrepant results of clinical studies, further stimulating the field to exploit the promise of mGlu(2)R as a target for schizophrenia treatment.

引用

页码：506 / 516

页数：11

共 50 条

[1] Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia
Fraley, Mark E.
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (09) : 1259 - 1275
[2] Novel allosteric modulators of metabotropic glutamate receptors subtypes 2 and 5 for the treatment of schizophrenia
Jones, C. K.
Xiang, Z.
Jones, P. J.
Byun, N. E.
Hackler, E. A.
Rodriguez, A. L.
Ayala, J. E.
Niswender, C. M.
Jadhav, S.
Sheffler, D. J.
Hammond, A. S.
Barret, R.
Thompson, A. D.
Williams, R.
Gore, J. C.
Weaver, C. D.
Lindsley, C. W.
Conn, P. J.
NEUROPHARMACOLOGY, 2008, 55 (04) : 603 - 603
[3] Screening for Positive Allosteric Modulators at Metabotropic Glutamate Receptors
Langmead, Chris
JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (07) : 903 - 904
[4] Recent advances in positive allosteric modulators of metabotropic glutamate receptors
Shipe, WD
Wolkenberg, SE
Williams, DL
Lindsley, CW
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (04) : 449 - 457
[5] Allosteric Modulators of Metabotropic Glutamate Receptor 5 for Treatment of Schizophrenia
Conn, P. J.
Stauffer, S. R.
Zhou, S.
Manka, J.
Williams, R.
Noetzel, M. J.
Gregory, K. J.
Vinson, P.
Niswender, C. M.
Jones, C. K.
Steckler, T.
MacDonald, G.
Lindsley, C. W.
CURRENT NEUROPHARMACOLOGY, 2011, 9 : 11 - 12
[6] Photoswitchable allosteric modulators for metabotropic glutamate receptors
Gomez-Santacana, Xavier
Panarello, Silvia
Rovira, Xavier
Llebaria, Amadeu
CURRENT OPINION IN PHARMACOLOGY, 2022, 66
[7] Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators
Goudet, C
Kniazeff, J
Hlavackova, V
Malhaire, F
Maurel, D
Acher, F
Blahos, J
Prézeau, L
Pin, JP
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (26) : 24380 - 24385
[8] Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012)
Lindsley, Craig W.
Stauffer, Shaun R.
PHARMACEUTICAL PATENT ANALYST, 2013, 2 (01) : 93 - 108
[9] Metabotropic glutamate receptors: Agonists, antagonists and allosteric modulators
Augelli-Szafran, CE
Schwarz, RD
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 21 - 30
[10] MODELLING THE FUNCTION OF METABOTROPIC GLUTAMATE RECEPTORS ALLOSTERIC MODULATORS
Rovira, X.
Roche, D.
Serra, J.
Pin, J. -P.
Giraldo, J.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 78 - 78

← 1 2 3 4 5 →